Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Acinetobacter baumannii outer membrane proteins (AbOMPs) are a group of highly conserved proteins located on the surface of this Gram-negative bacterium, serving as essential components for its survival, virulence, and antibiotic resistance (Mani et al., 2021). These proteins include structural porins like OmpA, which facilitates biofilm formation and host cell adhesion, as well as complex assembly machineries like the BAM (beta-barrel assembly machinery) and Lpt (lipopolysaccharide transport) complexes (Geisinger & Isberg, 2017). Because A. baumannii is a leading cause of multidrug-resistant (MDR) nosocomial infections, these conserved OMPs have become primary targets for next-generation therapeutics. For example, the novel antibiotic zosurabalpin (RG6006) specifically targets the LptD/E complex to block the transport of lipopolysaccharides to the outer membrane, leading to bacterial cell death (Pahil et al., 2024). Similarly, the peptide darobactin targets BamA to disrupt the folding of essential outer membrane proteins (Imai et al., 2019). Other conserved OMPs, such as the iron-regulated transporter BauA, are exploited by "Trojan horse" antibiotics like cefiderocol to gain entry into the cell (Mani et al., 2021). These targets are particularly attractive because they are often essential for bacterial viability and are highly conserved across diverse clinical isolates, minimizing the immediate risk of target-based resistance (Singh et al., 2020).
Inhibition of the lipopolysaccharide (LPS) transport machinery via the LptD/E complex, disruption of outer membrane protein folding through the BamA subunit of the BAM complex, and exploitation of siderophore-mediated iron transporters like BauA for antibiotic delivery (Pahil et al., 2024; Imai et al., 2019; Mani et al., 2021).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acinetobacter baumannii outer membrane proteins (AbOMPs).